First place: China Pharmaceutical Group Co., Ltd.
Second place: Changjiang Pharmaceutical Group Co., Ltd.
Third place: Guangzhou Pharmaceutical Group Co., Ltd.
Fourth place: Hengrui Pharma.
Fifth place: China Resources Pharmaceutical Group Co., Ltd.
Sixth place: Modified Pharmaceutical Group Co., Ltd.
Seventh place: Shanghai Fosun Pharma (Group) Co., Ltd.
Eighth place: Shanghai Pharmaceutical (Group) Co., Ltd.
Ninth place: Qilu Pharmaceutical Group Co., Ltd.
Tenth place: Unacon Holding Group Co., Ltd.
China Pharmaceutical Group Co., Ltd., namely China Pharmaceutical Group, is the largest pharmaceutical and health industry group with the most complete industrial chain and the strongest comprehensive strength in China directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. It focuses on distribution, retail, research and development and production of health-related products, such as preventive treatment and diagnostic care. It has more than 65,438+0,500 subsidiaries, and six listed companies, including Sinopharm Holdings, Sinopharm Shares, Sinopharm Consistent, Tiantan Bio, Hyundai Pharmaceutical and China Traditional Chinese Medicine.
China Pharmaceutical Group Co., Ltd. is making every effort to promote the all-round development of the group's five platforms-modern logistics and distribution integrated operation platform, Industry-University-Research integrated scientific and technological innovation platform, national drug retail chain network, national narcotic drug distribution network, national biological product marketing and cold chain distribution network, national medical device consumables product distribution network, scientific instruments and medical devices, medical research and engineering design, international operation of medicine and overseas industries, medical exhibitions and media, and medical and health industries.
Pharmaceutical Group has a pharmaceutical distribution network covering 365,438+0 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers that meet international standards. It is the largest biological R&D and production enterprise in China, and undertakes more than 80% of the production tasks of vaccines under the national immunization program. The group has established production bases and medicinal materials bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infective drugs, anti-tumor drugs, cardiovascular and cerebrovascular drugs and respiratory drugs, and has the strongest applied drug research institutions and engineering design institutes in China.